Be part of our community by subscribing to our newsletters! Follow the steps below.

1. Subscribe to our Announcement Newsletter. You will receive our news about what do you need to know about our work and the resources available for you. You need to confirm your subscription by email (check your email box and confirm your subscription)

2. Choose your favorite writer. We constantly look for the top minds on the pharmaceutical marketing industry. You can subscribe to their article on their pages and receive every article on your inbox. 

3. Choose the Newsletter that better fits you needs. We recommend the Editor’s pick to receive everything you need to know in one weekly email. 

4. All our newsletters needs to be confirmed by email. After you subscribe on our webpage, you will receive an email asking for your confirmation by clicking a link. Click that link if you want to receive the newsletter. If you don’t receive the email, check your spam box and add our email to your safe sender list. If you address belongs to a company, you may need to forward your confirmation email to your tech department to ask them to add our domain to your company safe sender list. 

You can start here by subscribing to our main Newsletter. Confirm your subscription by clicking CONFIRM on the email you will receive after complete the subscription form.

Don’t forget to check for our other newsletters! Check this page for several options we have for all our users!

NEWSLETTER ANNOUCEMENTS

TPMG FEATURED WRITER NEWSLETTER

- Advertisement -

Centering Caregivers

A version of this article was previously published on PharmaPhorum. By now, we’re all (hopefully) getting accustomed to the concept of “patient-centricity.” However, another commonly overlooked but equally important group of healthcare stakeholders is caregivers. These are people–mostly women–who dedicate themselves to supporting the patient throughout their disease or treatment...

Partnering with Patients and Caregivers in Clinical Research

A version of this article was previously published in the Journal of mHealth One definition of patient-centricity is “Putting the patient first in an open and sustained engagement of the patient to respectfully and compassionately achieve the best experience and outcome for that person and their family” (Yeoman et al....

Trust and transparency in Pharma & healthcare: impact of...

A version of this article was previously published on PharmaPhorum. Trust in life science companies has fluctuated since the start of the pandemic. The reputation of COVID-19 vaccine makers understandably soared early on, as clinical trials were started and completed in record time, giving hopes to millions of people in...

Digital Opinion Leaders (DOLs): Who are they and how...

A version of this article was previously published in the Journal of mHealth. With our growing dependence on social media over the past decade, Digital Opinion Leaders–or “DOLs” for short–are becoming an increasingly important stakeholder group for Pharma teams to engage and consult. But who are these DOLs, and why...

Natalie Yeadon´s Newsletter

- Advertisement -

Centering Caregivers

A version of this article was previously published on PharmaPhorum. By now, we’re all (hopefully) getting accustomed to the concept of “patient-centricity.” However, another commonly overlooked but equally important group of healthcare stakeholders is caregivers. These are people–mostly women–who dedicate themselves to supporting the patient throughout their disease or treatment...

Partnering with Patients and Caregivers in Clinical Research

A version of this article was previously published in the Journal of mHealth One definition of patient-centricity is “Putting the patient first in an open and sustained engagement of the patient to respectfully and compassionately achieve the best experience and outcome for that person and their family” (Yeoman et al....

Trust and transparency in Pharma & healthcare: impact of...

A version of this article was previously published on PharmaPhorum. Trust in life science companies has fluctuated since the start of the pandemic. The reputation of COVID-19 vaccine makers understandably soared early on, as clinical trials were started and completed in record time, giving hopes to millions of people in...

Digital Opinion Leaders (DOLs): Who are they and how...

A version of this article was previously published in the Journal of mHealth. With our growing dependence on social media over the past decade, Digital Opinion Leaders–or “DOLs” for short–are becoming an increasingly important stakeholder group for Pharma teams to engage and consult. But who are these DOLs, and why...

EDITOR´S PICK

- Advertisement -

European Commission Grants Expanded Marketing Authorization for Gilead’s Biktarvy®...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has authorized a new low-dose tablet dosage form of Biktarvy® (bictegravir 30 mg/emtricitabine 120 mg/tenofovir alafenamide 15 mg tablets) and an extension of the indication for Biktarvy to treat HIV infection in virologically suppressed...

Teva Announces Appointment of Richard Francis as President and...

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (“Teva” or the “Company”) (NYSE and TASE: TEVA), today announced that the Company’s Board of Directors has appointed Richard Francis as President and Chief Executive Officer, effective January 1, 2023. In order to facilitate an orderly transition, Kåre Schultz and the Teva...

World-First Inhaled COVID-19 Vaccine, Developed in Partnership Between Aerogen®...

GALWAY, Ireland--(BUSINESS WIRE)--Late in 2021, Aerogen® (Galway, Ireland) and CanSinoBIO (SSE: 688185, HKEX: 06185) (Tianjin, China) announced a development and commercial supply partnership for the inhaled delivery of CanSinoBIO’s Recombinant Novel Coronavirus Vaccine Convidecia Air™ utilizing Aerogen’s proprietary aerosol drug delivery technology. In 2022 Convidecia Air™ was granted Emergency Use...

PointClickCare Announces Real World Data Collaboration with Pfizer

MISSISSAUGA, Ontario--(BUSINESS WIRE)--PointClickCare Technologies, a leading healthcare technology platform enabling meaningful collaboration and access to real‐time insights, today announced a strategic collaboration with Pfizer Inc. to provide real world insights into the population at high risk of age-related disorders, which is aligned with PointClickCare’s mission to protect and support...

LOOK WHO IS ON THE MOVE!

Dr. Ravi Karra Joins Advanced Clinical to Accelerate Global...

CHICAGO--(BUSINESS WIRE)--Advanced Clinical, a clinical development and strategic resourcing organization committed to providing a better clinical experience across the drug development journey, is pleased to announce that Dr. Ravi Karra has been appointed Vice President, Oncology. As a subject matter expert in brain tumors, melanoma and head and neck cancer...

Nimble Therapeutics names Pete Gough as Chief Scientific Officer

MADISON, Wis.--(BUSINESS WIRE)--Nimble Therapeutics, an industry-leading peptide therapeutics company, today announced the appointment of Pete Gough, D. Phil. as Chief Scientific Officer (CSO). In this newly created role, Dr. Gough will spearhead the expansion of Nimble’s internal drug discovery capabilities that will enable further development of its own pipeline...

insitro Appoints Philip Tagari, Industry-Leading Scientist and Drug Hunter,...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--insitro, a machine learning-powered drug discovery and development company, today announced that Philip Tagari has been appointed as chief scientific officer. Tagari joins insitro following a 24-year career at Amgen, where he has led the organization's research platforms for over a decade as vice president,...

Akili Announces ADHD Expert Dr. Scott Kollins to Join...

BOSTON--(BUSINESS WIRE)--Akili, Inc., a leading commercial digital medicine company, today announced the appointment of Scott Kollins, Ph.D., as chief medical officer, effective December 1, 2022. Dr. Kollins will report to Akili’s chief operating officer and join the company’s executive team. “Dr. Kollins is one of the nation’s most respected key...

INDUSTRY NEWS

- Advertisement -

Ellipses Pharma Presents Design of Newly Initiated Phase 1/2a...

LONDON--(BUSINESS WIRE)--Ellipses Pharma Limited (“Ellipses”), a global drug development company focused on accelerating the development of new oncology treatments, will present a “Trial in Progress” poster detailing the design of a Phase 1/2 trial of vosilasarm (EP0062) in advanced breast cancer at the San Antonio Breast Cancer Symposium (SABCS)...

Clarify Health Recognized for Innovation in Patient Recruitment in...

SAN FRANCISCO--(BUSINESS WIRE)--For the third time this year, Clarify Health, a leading healthcare analytics platform company, is being honored by Frost & Sullivan. This award is for its innovation in accelerating patient recruitment in clinical trials. The 2022 North American Patient Recruitment IT Solutions New Product Innovation Award recognizes...

Memgen Reports Results From Its First-In-Human Clinical Trial of...

HOUSTON--(BUSINESS WIRE)--Memgen, Inc., a biopharmaceutical company developing potentially life-saving cancer immunotherapies, presented the first clinical data for MEM-288, its oncolytic viral therapy, at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting in Boston, MA. The interim results from this ongoing first-in-human Phase 1 trial indicate that MEM-288 is...

Spirita Oncology, LLC Initiates a Phase 1 Clinical Trial...

BOSTON--(BUSINESS WIRE)--Spirita Oncology, LLC, has initiated a Phase 1 clinical trial of anti-cancer agent E6201 in combination with dabrafenib in patients with BRAF V600-mutated metastatic melanoma that has spread to the central nervous system. There are approximately 47,000 new cases of metastatic melanoma in the U.S. each year, with approximately...

REGULATORY AFFAIRS

Innoviva Announces FDA Acceptance and Priority Review of New...

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the new drug application (NDA) for SUL-DUR, an investigational drug for the treatment of...

Ferring Receives U.S. FDA Approval for REBYOTA® (fecal microbiota,...

SAINT-PREX, Switzerland & PARSIPPANY, N.J.--(BUSINESS WIRE)--Ferring Pharmaceuticals today announced the U.S. Food and Drug Administration (FDA) approved REBYOTA® (fecal microbiota, live-jslm), a novel first-in-class microbiota-based live biotherapeutic indicated for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older, following antibiotic treatment...

Aldeyra Therapeutics Submits New Drug Application to the U.S....

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for topical ocular reproxalap, an investigational new drug candidate, for the treatment of signs and symptoms of dry eye disease. The NDA submission is...

ANANDA Scientific Announces FDA Approval of the IND for...

NEW YORK & GREENWOOD VILLAGE, Colo.--(BUSINESS WIRE)--ANANDA Scientific Inc., a research focused bio-pharmaceutical company today announced approval by the US Food and Drug Administration (FDA) of the IND application for a clinical trial evaluating Nantheia™ A1002N5S, an investigational drug using cannabidiol (CBD) in ANANDA’s proprietary Liquid Structure™ delivery technology...
Get a free copy of "Cracking the Generics Code"

Looks like you are using an ad-blocking browser extension. We request you to whitelist our website on the ad-blocking extension and refresh your browser to view the content.